A Study of LY3039478 in Participants With Advanced Cancer
Eli Lilly and Company
The purpose of this study is to find a recommended dose level of LY3039478 that can safely
be taken by participants with advanced cancer or cancer that has spread to other parts of
the body, including but not limited to lymphoma. The study will also explore changes to
various markers in blood cells and tissue. Finally, the study will help to document any
tumor activity this drug may have.
A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL
Eli Lilly and Company
Phase 1/Phase 2
The main purpose of this study is to evaluate the safety of the study drug known as
LY3039478 in combination with dexamethasone in participants with T-cell acute lymphoblastic
leukemia or T-cell lymphoblastic lymphoma (T-ALL/T-LBL).
The main purpose of this study is to investigate the safety of the study drug known as
LY3039478 and evaluate two different formulations of LY3039478 in healthy participants. Part
A has three periods. Either LY3039478 or placebo will be given once by mouth in each period.
Part B has two periods. Participants will receive both formulations of LY3039478, by mouth,
over the course of the study. Both parts of the study will also explore how much LY3039478
gets into the bloodstream and how long it takes the body to get rid of it. Information about
any side effects will also be collected. Participants may only enroll in one part. The study
will last at least 33 days, not including screening. Screening must be performed up to 30
days before enrollment.
Part B was added by protocol amendment approved in April, 2016.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.